INSTINCT BIO TECHNICAL CO HOLDINGS INC.
No SEC Form 4 filings for $BIOT in the last 30 days.
See all $BIOT insider activity →Instinct Bio (NASDAQ:BIOT) secured a site in Jakarta for its GENREVER CLINIC, targeting a December 2026 opening. Subscription tiers are set at $400, $1,000, and $3,000 monthly. The company also announced product development plans with Invitrx Therapeutics and PT PARVA CANDELA, aiming for 2026 production starts.
Instinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) said its subsidiaries entered a Memorandum of Agreement with Invitrx Therapeutics, Inc. to expand GENREVER into the U.S. via a planned trademark license and U.S. GMP manufacturing, and to explore supplying exosomes and conditioned media for regenerative medicine initiatives in Indonesia. Definitive deals and regulatory approvals are pending.
Instinct Bio Technical Company Holdings Inc. (NASDAQ: BIOT) said it will launch GENRÊVER CLINIC in Indonesia, a subscription-model beauty clinic under its Japanese brand with a cancel-anytime membership structure. The company plans about $1 million to open five directly operated sites starting in Jakarta, Surabaya, Bandung, Medan and Bali, with Dr. Mario Damianus Daniel Hadinoto involved.
Over the past 7 days, alphai's AI scored 1 news story mentioning BIOT (INSTINCT BIO TECHNICAL CO HOLDINGS INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent BIOT coverage spans financial news and corporate actions.
The clinic launch could boost future revenue and market visibility.
The MOA is a growth and commercialization framework, but it is not yet a definitive deal or regulatory-approved product launch.
The company is pursuing a new, recurring-revenue consumer aesthetics platform in Indonesia, which could expand revenue visibility but is still early-stage and execution-dependent.
The proposed $150M equity facility is likely to keep pressure on BIOT shares due to dilution risk, especially after a -51% close and -20% after-hours drop.
alphai scores every news story that mentions BIOT with an AI model for sentiment and relevance, and aggregates insider trades from INSTINCT BIO TECHNICAL CO HOLDINGS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Instinct Bio (NASDAQ:BIOT) secured a site in Jakarta for its GENREVER CLINIC, targeting a December 2026 opening. Subscription tiers are set at $400, $1,000, and $3,000 monthly. The company also announced product development plans with Invitrx Therapeutics and PT PARVA CANDELA, aiming for 2026 production starts.
1 min readInstinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) said its subsidiaries entered a Memorandum of Agreement with Invitrx Therapeutics, Inc. to expand GENREVER into the U.S. via a planned trademark license and U.S. GMP manufacturing, and to explore supplying exosomes and conditioned media for regenerative medicine initiatives in Indonesia. Definitive deals and regulatory approvals are pending.
3 min readInstinct Bio Technical Company Holdings Inc. (NASDAQ: BIOT) said it will launch GENRÊVER CLINIC in Indonesia, a subscription-model beauty clinic under its Japanese brand with a cancel-anytime membership structure. The company plans about $1 million to open five directly operated sites starting in Jakarta, Surabaya, Bandung, Medan and Bali, with Dr. Mario Damianus Daniel Hadinoto involved.
3 min readInstinct Bio (BIOT) shares fell 51.46% to $1.33 Tuesday and dropped another 20.30% in after-hours to $1.06. The Nasdaq-listed biotech completed a business combination with Relativity Acquisition Corp. It entered an indicative term sheet for an equity purchase facility to sell up to $150M of common stock over three years, priced near VWAP less a discount, to fund development and working capital.
3 min read
